Glaukos touts Ph2 glaucoma trial for drug-eluting implant
Glaukos (NYSE:GKOS) touted data today from a Phase II trial of its travoprost intraocular implant in a 12-month cohort of glaucoma patients. The company’s iDose device is placed during a micro-invasive procedure and filled with a special formulation of travoprost – a drug used to reduce intraocular pressure. The implant continuously delivers therapeutic levels of travoprost within the eye and when it’s depleted, the iDose is removed and replaced. Get the full story at our sister site, Drug Delivery Business News. The post Glaukos touts Ph2 glaucoma trial for drug-eluting implant appeared first on MassDevice.
CONCLUSIONS: The number of partially preserved retinal ganglion cells in the erythropoietin-treated group suggests that erythropoietin exerts a neuroprotective effect on oligemic/ischemic retinas. This effect could be re lated to the down-modulation of glial reactivity, usually observed in hypoxic conditions, clinically observed during glaucoma or retinal artery occlusion conditions. Therefore, glial reactivity may enhance neurodegeneration in hypoxic conditions, like normal-tension glaucoma and retinal ischemia, an d erythropoietin is thus a candidate to be clinically applied after the detection of decreased retinal blood flow.
A 15-year-old girl with history of unilateral sporadic aniridia presented with decreased vision and eye pain in the left eye (Fig 1A). Fundus examination of right eye revealed a capillary hemangioma inferonasally with circumferential exudation consistent with Von Hippel-Lindau Syndrome (VHL) (Fig 1B). Examination of the left eye revealed complete chronic exudative retinal detachment and neovascular glaucoma presumed to be due to capillary hemangioma (Fig 1C). Genetic testing and a systemic work-up were performed.
A 3-year-old boy presented to the pediatric ophthalmology department with a diagnosis of bilateral congenital megalocornea. On observation, he had extremely large corneal diameters with minimal sclera show (Fig 1A), and the appearance of large palpebral apertures. There was a corneal optical aberration when viewed from the side (left eye; Fig 1B) and when magnified, it is possible to view the angle structures (right eye; Fig 1C) without the aid of a gonioscopy lens. Apart from the corneas, all anterior segment structures appeared to be normal, with no evidence of glaucoma.
ConclusionsA patient with neurosarcoidosis presenting with compressive ischemic optic disc edema and neovascular glaucoma is described, increasing the diversity of clinical presentations and confirming the diagnostic challenge of neurosarcoidosis.
Sturge-Weber syndrome (SWS) is a neurocutaneous disorder associated with port wine birthmark, leptomeningeal capillary malformations, and glaucoma. It is associated with an unpredictable clinical course. Due to its rarity and complexity, many physicians are unaware of the disease and its complications. A major focus moving ahead will be to turn knowledge gaps and unmet needs into new research directions.
Authors: Jait A, Amazouzi A, Jait N, Njoya JM, Lezrek O, Cherkaoui O PMID: 29656827 [PubMed - as supplied by publisher]
Authors: Chokrani H, Bengarai W, Tabet Aouel S, Berraho A PMID: 29655577 [PubMed - as supplied by publisher]
Clinical&Experimental Ophthalmology,Volume 46, Issue 3, Page 211-212, April 2018.
This study looks at the viability of MIGS in patients who don’t need or may have already had cataract surgery, so it’s a vital addition to our growing body of evidence supporting MIGS,” Compare trial medical monitor Dr. Iqbal Ahmed said in a prepared release. Ivantis said the 152-patient trial was the first to compare two minimally invasive glaucoma surgery device for treating open-angle glaucoma in a standalone procedure. The study aimed to compare safety and effectiveness of both devices in lowering IOP and reducing eye-drop medication. Results at one year showed that 47% of eyes treated with the Hydrus...